Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.

Autor: Dogra S; Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India., D S K; Manipal Hospital, Bangalore, India., Budamakuntla L; Bowring and Lady Curzon Hospitals, Bangalore, India., Srinivas CR; PSG Hospital, Coimbatore, India., Khopkar U; Seth GS Medical College and KEM Hospital, Mumbai, India., Gupta S; Skin and Laser Centre, New Delhi, India., Shetty N; AJ Institute of Medical Sciences, Mangalore, India., Pratap DV; Durgabhai Deshmukh Hospital, Hyderabad, India., Gopal MG; Kempegowda Institute of Medical Sciences, Bangalore, India., Rao TN; King George Hospital, Visakhapatnam, India., Garg V; Maulana Azad College and Lok Nayak Hospital, New Delhi, India., Sumathy TK; M S Ramaiah Memorial Hospital, Bangalore, India., Saraswat A; Indushree Skin Clinic, Lucknow, India., Bhat R; Father Muller Medical College and Hospital, Mangalore, India., Kura M; Grant Medical College and JJ Group of Hospitals, Mumbai, India., Pandey N; DermaKlinic Skin, Laser and Cosmetic Clinic, Lucknow, India., Shah R; Apollo Hospital, Hyderabad, India., Sai Krishna K; Sri Sai Skin Clinic, Hyderabad, India., Padmaja D; Sumana Hospital, Hyderabad, India., Manmohan G; Derma Skin Clinic, Hyderabad, India., M S R; Biocon Research Limited, Bangalore, India., Barve A; Biocon Research Limited, Bangalore, India. Electronic address: Abhijit.Barve@biocon.com., Montero E; Biocon Research Limited, Bangalore, India; Center of Molecular Immunology, Havana, Cuba.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2015 Aug; Vol. 73 (2), pp. 331-3.e1.
DOI: 10.1016/j.jaad.2015.03.040
Databáze: MEDLINE